Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says
This article was originally published in The Tan Sheet
Executive Summary
Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results
You may also be interested in...
Allegra Faces Increasing Challenges In Rx Drug Arena
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis
Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings
Medco Promotes Wyeth’s Alavert As Part Of “Generics First” Program
Wyeth's Alavert antihistamine allergy drug is featured in pharmacy benefits manager Medco Health Solutions' Generics First program